AbbVie Inc (NYSE:ABBV) shares are sliding on Thursday after the company cut its fourth‑quarter and full‑year 2025 guidance, was downgraded by Wolfe Research and pushed back on reports that it’s pursuing a major acquisition.
What Happened: AbbVie said it now expects to take a $1.3 billion charge for acquired IPR&D and milestone expenses in the fourth-quarter of 2025. That will reduce adjusted earnings by 71 cents per share.
The company now sees 2025 …